Answer B {#s3}
========

Multiple patchy, mid-myocardial, high-intensity signal areas in the inferolateral wall on T2-weighted images (B) and increased T2 mapping values on the short-axis images (G) are highly specific for oedema. These areas have high signal intensity on early (C) and late (D,H) sequences, suggesting hyperaemia with capillary leakage and increased extracellular space, respectively. Furthermore, increased native T1 mapping values in all layers but predominantly in the subepicardium of the entire lateral wall (F) are in keeping with extensive myocardial injury ([figure 1](#F1){ref-type="fig"}). Taken in combination, these findings meet the updated Lake Louise criteria for acute myocarditis.[@R1] Despite extensive oedema, stress (Takotsubo) cardiomyopathy (option D) can be excluded by ventricular morphology and the presence of LGE,[@R2] and multiple embolic myocardial infarctions (options A and E) are excluded by the non-ischaemic pattern of LGE.[@R3] Finally, based on the CMR, cardiac sarcoidosis (option C) cannot be easily distinguished from acute autoimmune myocarditis. However, the clinical presentation and absence of pulmonary changes make the latter diagnosis the most likely.[@R4] Cardiac biopsy might definitively differentiate, but is not routinely performed due to associated procedural risk. The patient was treated with corticosteroids and monoclonal antibodies and responded well. The pathophysiological mechanisms underlying cardiac manifestations of inflammatory bowel disease are incompletely understood but may occur in up to one-third of patients with inflammatory bowel disease.[@R5]
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